<DOC>
	<DOCNO>NCT01327547</DOCNO>
	<brief_summary>To describe liver enzyme elevation patient coinfected HIV either Hepatitis C ( HCV ) and/or Hepatitis B ( HBV ) receive maraviroc placebo combination current suppressive anti-HIV drug therapy .</brief_summary>
	<brief_title>A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Coinfection</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<mesh_term>Anti-Retroviral Agents</mesh_term>
	<criteria>HIV coinfected HCV and/or HBV . Undetectable HIV1 RNA least 3 month prior screen visit Treatment current antiretroviral therapy ( 36 drug exclude lowdose ritonavir ) least 5 month . Currently receive maraviroc . Active opportunistic infection . ALT and/or AST &gt; 5x upper limit normal . Direct bilirubin &gt; 1.5x upper limit normal . Severe decompensated liver disease . Liver disease unrelated viral hepatitis infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>HIV coinfection</keyword>
	<keyword>maraviroc</keyword>
	<keyword>CCR5 blocker</keyword>
	<keyword>entry inhibitor</keyword>
	<keyword>liver disease</keyword>
	<keyword>viral hepatitis</keyword>
</DOC>